These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 4713784)

  • 1. Tumor immunity in melanoma patients as assessed by colony inhibition and microcytotoxicity methods: a preliminary report.
    Byrne M; Heppner G; Stolbach L; Cummings F; McDonough E; Calabresi P
    Natl Cancer Inst Monogr; 1973 Jun; 37():3-8. PubMed ID: 4713784
    [No Abstract]   [Full Text] [Related]  

  • 2. Cellular immunity to human tumor-associated antigens. A review.
    Herberman RB
    Isr J Med Sci; 1973 Mar; 9(3):300-7. PubMed ID: 4575654
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of an in vitro microcytotoxicity test to assess human tumor-specific cell-mediated immunity and its serum-mediated abrogation.
    Levy NL
    Natl Cancer Inst Monogr; 1973 Jun; 37():85-92. PubMed ID: 4576707
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of autoimmunization with irradiated tumour cells on specific cell-mediated immunity in patients with malignant melanoma.
    Currie GA
    Proc R Soc Med; 1972 Feb; 65(2):144-7. PubMed ID: 4563684
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of anchorage-independent growth of human melanoma cells by a monoclonal antibody to a chondroitin sulfate proteoglycan.
    Harper JR; Reisfeld RA
    J Natl Cancer Inst; 1983 Aug; 71(2):259-63. PubMed ID: 6576184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demonstration of cell-mediated and blocking immune responses to tumor antigens in cancer patients with the colony-inhibition-in-gel test.
    Cummings FJ; Heppner GH; Stolbach L; Calabresi P
    Isr J Med Sci; 1973 Mar; 9(3):308-16. PubMed ID: 4710038
    [No Abstract]   [Full Text] [Related]  

  • 7. Cell-mediated and serum blocking reactivity to tumor antigens in patients with malignant melanoma.
    Heppner GH; Stolbach L; Byrne M; Cummings FJ; McDonough E; Calabresi P
    Int J Cancer; 1973 Mar; 11(2):245-60. PubMed ID: 4790694
    [No Abstract]   [Full Text] [Related]  

  • 8. [Immunology of malignant melanoma].
    Bourgoin JJ
    Ann Inst Pasteur (Paris); 1972 Apr; 122(4):789-807. PubMed ID: 4559237
    [No Abstract]   [Full Text] [Related]  

  • 9. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
    Rivoltini L; Radrizzani M; Accornero P; Squarcina P; Chiodoni C; Mazzocchi A; Castelli C; Tarsini P; Viggiano V; Belli F; Colombo MP; Parmiani G
    J Immunol; 1998 Aug; 161(3):1220-30. PubMed ID: 9686582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of cell-mediated reactivity and serum blocking factors in melanoma patients on chemotherapy.
    Cummings FJ; Heppner GH; Calabresi P
    Med Pediatr Oncol; 1975; 1(3):195-206. PubMed ID: 1232528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cytotoxic immunity indices of melanoma B16 growth in mice].
    Korosteleva TA; Veresova OV
    Vopr Onkol; 1980; 26(1):67-70. PubMed ID: 7355591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition and lysis of human melanoma by a CD3+, CD4+, CD8- T-cell clone restricted by HLA-A2.
    Darrow TL; Abdel-Wahab Z; Quinn-Allen MA; Seigler HF
    Cell Immunol; 1996 Aug; 172(1):52-9. PubMed ID: 8806806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evidence for tumor immunity in human malignant melanoma].
    Nagel GA
    Schweiz Med Wochenschr; 1970 Jun; 100(23):995-1000. PubMed ID: 4947017
    [No Abstract]   [Full Text] [Related]  

  • 14. Monoclonal antibodies to two determinants of melanoma-antigen p97 act synergistically in complement-dependent cytotoxicity.
    Hellström I; Brown JP; Hellström KE
    J Immunol; 1981 Jul; 127(1):157-60. PubMed ID: 6787119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of monoclonal antibodies to human melanoma-associated antigens.
    Imai K; Ng AK; Ferrone S
    J Natl Cancer Inst; 1981 Mar; 66(3):489-96. PubMed ID: 6162991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients.
    Takahashi T; Irie RF; Morton DL; Hoon DS
    Cell Immunol; 1997 Jun; 178(2):162-71. PubMed ID: 9225007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Spontaneous toxicity and "K"-cell activity in the peripheral lymphocytes of control subjects and melanoma patients].
    Peter HH; Pavie-Fischer J; Knoop F; Fridman WH; Cesarini JP; Roubin R; Aubert C; Kourilsky FM
    Verh Dtsch Ges Inn Med; 1975; 81():1213-6. PubMed ID: 1229443
    [No Abstract]   [Full Text] [Related]  

  • 18. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells.
    Visseren MJ; van Elsas A; van der Voort EI; Ressing ME; Kast WM; Schrier PI; Melief CJ
    J Immunol; 1995 Apr; 154(8):3991-8. PubMed ID: 7706738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of malignant melanoma with vaccinia virus.
    Roenigk HH; Deodhar S; St Jacques R; Burdick K
    Arch Dermatol; 1974 May; 109(5):668-73. PubMed ID: 4828533
    [No Abstract]   [Full Text] [Related]  

  • 20. The NK function elucidated with respect to effector cells, target cells and other immunological in vitro tests.
    Kristensen E
    Tokai J Exp Clin Med; 1983 Dec; 8(5-6):449-53. PubMed ID: 6681340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.